These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 16966395)
1. Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Ménez C; Buyse M; Besnard M; Farinotti R; Loiseau PM; Barratt G Antimicrob Agents Chemother; 2006 Nov; 50(11):3793-800. PubMed ID: 16966395 [TBL] [Abstract][Full Text] [Related]
2. Modulation of intestinal barrier properties by miltefosine. Menez C; Buyse M; Chacun H; Farinotti R; Barratt G Biochem Pharmacol; 2006 Feb; 71(4):486-96. PubMed ID: 16337152 [TBL] [Abstract][Full Text] [Related]
3. Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B. Ménez C; Legrand P; Rosilio V; Lesieur S; Barratt G Mol Pharm; 2007; 4(2):281-8. PubMed ID: 17397240 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Seifert K; Croft SL Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670 [TBL] [Abstract][Full Text] [Related]
6. Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani. Tripathi P; Jaiswal AK; Dube A; Mishra PR Int J Biol Macromol; 2017 Dec; 105(Pt 1):625-637. PubMed ID: 28716750 [TBL] [Abstract][Full Text] [Related]
7. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Rakotomanga M; Saint-Pierre-Chazalet M; Loiseau PM Antimicrob Agents Chemother; 2005 Jul; 49(7):2677-86. PubMed ID: 15980336 [TBL] [Abstract][Full Text] [Related]
8. Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleates. Pham TT; Barratt G; Michel JP; Loiseau PM; Saint-Pierre-Chazalet M Colloids Surf B Biointerfaces; 2013 Jun; 106():224-33. PubMed ID: 23434716 [TBL] [Abstract][Full Text] [Related]
9. A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani. Vacchina P; Norris-Mullins B; Carlson ES; Morales MA Parasit Vectors; 2016 Dec; 9(1):621. PubMed ID: 27906059 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani. Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145 [TBL] [Abstract][Full Text] [Related]
11. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445 [TBL] [Abstract][Full Text] [Related]
12. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Luque-Ortega JR; Rivas L Antimicrob Agents Chemother; 2007 Apr; 51(4):1327-32. PubMed ID: 17283192 [TBL] [Abstract][Full Text] [Related]
13. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Papagiannaros A; Bories C; Demetzos C; Loiseau PM Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367 [TBL] [Abstract][Full Text] [Related]
14. The effects of clofazimine, niclosamide & amphotericin B, on electron transport of Leishmania donovani promastigotes. Datta G; Bera T Indian J Med Res; 2000 Jul; 112():15-20. PubMed ID: 11006656 [TBL] [Abstract][Full Text] [Related]
15. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes. Saint-Pierre-Chazalet M; Ben Brahim M; Le Moyec L; Bories C; Rakotomanga M; Loiseau PM J Antimicrob Chemother; 2009 Nov; 64(5):993-1001. PubMed ID: 19749205 [TBL] [Abstract][Full Text] [Related]
16. Development of antileishmanial lipid nanocomplexes. Pham TT; Gueutin C; Cheron M; Abreu S; Chaminade P; Loiseau PM; Barratt G Biochimie; 2014 Dec; 107 Pt A():143-53. PubMed ID: 24952352 [TBL] [Abstract][Full Text] [Related]
17. Development of a semi-automated colorimetric assay for screening anti-leishmanial agents. Ganguly S; Bandyopadhyay S; Sarkar A; Chatterjee M J Microbiol Methods; 2006 Jul; 66(1):79-86. PubMed ID: 16316700 [TBL] [Abstract][Full Text] [Related]
18. In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani. Seifert K; Munday J; Syeda T; Croft SL J Antimicrob Chemother; 2011 Apr; 66(4):850-4. PubMed ID: 21393188 [TBL] [Abstract][Full Text] [Related]
19. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Paris C; Loiseau PM; Bories C; Bréard J Antimicrob Agents Chemother; 2004 Mar; 48(3):852-9. PubMed ID: 14982775 [TBL] [Abstract][Full Text] [Related]
20. Antileishmanial activity of drug infused mini-agar plates on Leishmania donovani promastigotes. Muniaraj M; Sinha PK; Das P Trop Biomed; 2010 Dec; 27(3):657-61. PubMed ID: 21399608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]